AIM: The relative afferent pupillary defect (RAPD) is an important clinical sign of asymmetrical retinal ganglion cell and axonal damage. Although glaucoma essentially affects bilateral eyes, a subset of patients manifests asymmetrical glaucomatous optic neuropathy (GON), which exhibits an RPAD in the more advanced eyes. However, the degree to which axonal loss occurs before an RAPD is clinically detectable has not been substantiated. The purpose of this study is to assess the relationship between the depth of a clinically detectable RAPD and the reduction ratio of retinal nerve fiber layer (RNFL) thickness in the more advanced eyes relative to that in the contralateral less advanced eyes of patients with asymmetrical GON. METHODS: Enrolled were 29 consecutive glaucoma patients with the clinically detectable RAPD. An RAPD was quantified by placing log-scaled neutral density filters over the less advanced eyes while performing the swinging flashlight test. Average RNFL thickness was determined using the Fast RNFL thickness programme of optical coherence tomography 3000. Correlation coefficient and Linear regression analyses were used in assessing the relationship between the RAPD and the ratio of RNFL thickness in the more advanced eyes relative to that in the less advanced. RESULTS: RAPD ranged from 0.6 to 2.4 log units. The log-scaled RAPD had a statistically significantly inversed correlation with the average RNFL thickness ratio (r(s) = -0.729, p<0.0001). Linear regression analysis found an equation that the average RNFL thickness ratio in the more affected eyes relative to that in the less advanced (%) = (0.827-0.169xRAPD (log units))x100 (R(2) = 0.557, p<0.0001). CONCLUSIONS: When an RAPD is clinically detected, the RNFL thickness in the more advanced eyes was in average reduced to about 73% of that in the less advanced.
AIM: The relative afferent pupillary defect (RAPD) is an important clinical sign of asymmetrical retinal ganglion cell and axonal damage. Although glaucoma essentially affects bilateral eyes, a subset of patients manifests asymmetrical glaucomatous optic neuropathy (GON), which exhibits an RPAD in the more advanced eyes. However, the degree to which axonal loss occurs before an RAPD is clinically detectable has not been substantiated. The purpose of this study is to assess the relationship between the depth of a clinically detectable RAPD and the reduction ratio of retinal nerve fiber layer (RNFL) thickness in the more advanced eyes relative to that in the contralateral less advanced eyes of patients with asymmetrical GON. METHODS: Enrolled were 29 consecutive glaucomapatients with the clinically detectable RAPD. An RAPD was quantified by placing log-scaled neutral density filters over the less advanced eyes while performing the swinging flashlight test. Average RNFL thickness was determined using the Fast RNFL thickness programme of optical coherence tomography 3000. Correlation coefficient and Linear regression analyses were used in assessing the relationship between the RAPD and the ratio of RNFL thickness in the more advanced eyes relative to that in the less advanced. RESULTS: RAPD ranged from 0.6 to 2.4 log units. The log-scaled RAPD had a statistically significantly inversed correlation with the average RNFL thickness ratio (r(s) = -0.729, p<0.0001). Linear regression analysis found an equation that the average RNFL thickness ratio in the more affected eyes relative to that in the less advanced (%) = (0.827-0.169xRAPD (log units))x100 (R(2) = 0.557, p<0.0001). CONCLUSIONS: When an RAPD is clinically detected, the RNFL thickness in the more advanced eyes was in average reduced to about 73% of that in the less advanced.
Authors: Theodore Krupin; Jeffrey M Liebmann; David S Greenfield; Lisa F Rosenberg; Robert Ritch; John W Yang Journal: Ophthalmology Date: 2005-03 Impact factor: 12.079
Authors: D Cettomai; G Hiremath; J Ratchford; A Venkatesan; B M Greenberg; J McGready; C A Pardo; D A Kerr; E Frohman; L J Balcer; J C McArthur; P A Calabresi Journal: Neurology Date: 2010-09-01 Impact factor: 9.910
Authors: M Waisbourd; B Lee; M H Ali; L Lu; P Martinez; B Faria; A Williams; M R Moster; L J Katz; G L Spaeth Journal: Eye (Lond) Date: 2015-06-26 Impact factor: 3.775
Authors: Andrew J Tatham; Daniel Meira-Freitas; Robert N Weinreb; Amir H Marvasti; Linda M Zangwill; Felipe A Medeiros Journal: Invest Ophthalmol Vis Sci Date: 2014-01-29 Impact factor: 4.799
Authors: Dolly S Chang; Michael V Boland; Karun S Arora; Wasu Supakontanasan; Bei Bei Chen; David S Friedman Journal: Invest Ophthalmol Vis Sci Date: 2013-08-19 Impact factor: 4.799
Authors: Carolina P B Gracitelli; Andrew J Tatham; Linda M Zangwill; Robert N Weinreb; Ricardo Y Abe; Alberto Diniz-Filho; Augusto Paranhos; Saif Baig; Felipe A Medeiros Journal: Invest Ophthalmol Vis Sci Date: 2016-04 Impact factor: 4.799